This paper is looking at a small scale human study in SA with mostly younger participants, which does make the results difficult to apply to the wider population.
They also only use a 4 week dosing schedule where the suggestion and actual rollout in the UK is following the 10-12 week schedule between first and second doses.
The variant in question seems to escape the majority of Antibody detection, but T-Cells still seem to provide significant protection against severe disease and death.
The main published results aren't yet from human scale studies but here is one in hamsters showing a comparison in organ damage and results between unvaccinated and vaccinated with the Oxford/AZ vaccine.
They also only use a 4 week dosing schedule where the suggestion and actual rollout in the UK is following the 10-12 week schedule between first and second doses.
The variant in question seems to escape the majority of Antibody detection, but T-Cells still seem to provide significant protection against severe disease and death.
https://academic.oup.com/cid/advance-article/doi/10.1093/cid...
https://www.biorxiv.org/content/10.1101/2021.03.11.435000v1
The main published results aren't yet from human scale studies but here is one in hamsters showing a comparison in organ damage and results between unvaccinated and vaccinated with the Oxford/AZ vaccine.
reply